{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:57:29Z","timestamp":1790657849196,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020648","name":"Royal College of Physicians of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000395","name":"Royal College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23246","type":"journal-article","created":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T07:44:53Z","timestamp":1701589493000},"page":"e23246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines \u2013 A prospective multi-center study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-9075","authenticated-orcid":false,"given":"Pawat","family":"Phuensan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarongkorn","family":"Sirimongkolkasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terapong","family":"Tantawichien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeerath","family":"Phannajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pokrath","family":"Hansasuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prawat","family":"Chantharit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adisorn","family":"Wongsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pusit","family":"Fuengfoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anutra","family":"Chittinandana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriengsak","family":"Vareesangthip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Methee","family":"Chayakulkeeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sureeporn","family":"Jangsirikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araya","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanyika","family":"Wanvimonsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poramed","family":"Winichakoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattagan","family":"Kajeekul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichai","family":"Prayoonwiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6866-6886","authenticated-orcid":false,"given":"Rungsun","family":"Rerknimitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e23246_bib1","series-title":"Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico","author":"Dunkle","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e23246_bib2","year":"2021"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23246_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.heliyon.2023.e23246_bib4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.heliyon.2023.e23246_bib5","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.heliyon.2023.e23246_bib6","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10317","key":"10.1016\/j.heliyon.2023.e23246_bib8","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e23246_bib9","series-title":"SAGE Working Group on COVID-19 Vaccines, Evidence Assessment: Sinopharm\/BBIBP COVID-19 Vaccine","year":"2021"},{"issue":"44","key":"10.1016\/j.heliyon.2023.e23246_bib10","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.vaccine.2021.09.052","article-title":"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia","volume":"39","author":"Fadlyana","year":"2021","journal-title":"Vaccine"},{"issue":"10269","key":"10.1016\/j.heliyon.2023.e23246_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e23246_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104073","article-title":"Heterologous ChAdOx1\/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: the pragmatic, multi-center, three-arm, partially randomized HEVACC trial","volume":"80","author":"B\u00e1nki","year":"2022","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23246_bib14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40620-022-01247-7","article-title":"Humoral immunogenicity and tolerability of heterologous Chad\/BNT compared with homologous BNT\/BNT and Chad\/ChAd SARS-CoV-2 vaccination in hemodialysis patients : a multicenter prospective observational study","volume":"35","author":"Haase","year":"2022","journal-title":"J. Nephrol."},{"key":"10.1016\/j.heliyon.2023.e23246_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103761","article-title":"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants","volume":"75","author":"Gro\u00df","year":"2022","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23246_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jinf.2022.01.038","article-title":"Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England","volume":"84","author":"Westrop","year":"2022","journal-title":"J. Infect."},{"issue":"10303","key":"10.1016\/j.heliyon.2023.e23246_bib17","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23246_bib18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jfma.2022.02.020","article-title":"Immune response and safety of heterologous ChAdOx1-nCoV-19\/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination","volume":"121","author":"Sheng","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"issue":"10319","key":"10.1016\/j.heliyon.2023.e23246_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23246_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2029111","article-title":"Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study","volume":"18","author":"Wanlapakorn","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"issue":"23","key":"10.1016\/j.heliyon.2023.e23246_bib21","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/j.vaccine.2022.04.043","article-title":"Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: real-world data","volume":"40","author":"Wanlapakorn","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2023.e23246_bib22","first-page":"689","article-title":"Comparison of SARS-COV-2 antibody production by 2-dose CoronaVac, 2-dose Vaxzevria, 2-dose CoronaVac-Vaxzevria heterologous vaccination and post-infection","volume":"52","author":"Yorsaeng","year":"2021","journal-title":"Southeast Asian J. Trop. Med. Publ. Health"},{"issue":"10296","key":"10.1016\/j.heliyon.2023.e23246_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"issue":"10267","key":"10.1016\/j.heliyon.2023.e23246_bib24","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23246_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jmv.27289","article-title":"The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older","volume":"94","author":"Karamese","year":"2022","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23246_bib26","first-page":"78","article-title":"COVID\u201019 in olderadults antibody responses of inactivated SARS\u2010CoV\u20102 (Vero cell\u2010SINOVAC) vaccine for elderly comparing with younger","volume":"9","author":"Ozsezikli","year":"2021","journal-title":"IntJ Healthcare Sci"},{"key":"10.1016\/j.heliyon.2023.e23246_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.36519\/idcm.2022.115","article-title":"SARS-CoV-2 IgG antibody levels after inactivated vaccine (CoronaVac) among elderly","volume":"2","author":"Din\u00e7","year":"2022","journal-title":"Infect Dis Clin Microbiol"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023104543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023104543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:28:31Z","timestamp":1790656111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023104543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023104543"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23246","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines \u2013 A prospective multi-center study","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23246"}}